NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO.,LTD.

Otros idiomas Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.

Acciones

603707

CNE100002WP3

Precio de cierre Shanghai S.E. Otros sitios de cotización 00:00:00 08/05/2024			Varia. Cinco días.	Varia. 1 de enero.
13,5 ^CNY	-1,39 %		-1,46 %	-10,00 %

01/05	NKFPharma obtiene el visto bueno para registrar un nuevo tratamiento contra el cáncer	MT
27/04	Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Resultados del primer trimestre finalizado el 31 de marzo de 2024	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

NKFPharma Gets Nod to Register New Cancer Treatment	01/05
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	27/04
King-Friend Biochemical Pharmaceutical's Unit Gets US FDA Nod to Market Oxaliplatin Injection	16/01
NKFPharma Gets Certificate to Register Voriconazole for Injection	11/01
Nanjing King-Friend’s Cancer Drug Get US FDA Nod	28/12
King-Friend Biochemical Pharma Gets Certificates for Registration of Micafungin Sodium for Injection	22/12
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/10/23
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. Announces an Exclusive Licensing Agreement with Tonghua Dongbao Pharmaceutical Co., Ltd. to Commercialize Three Insulin Biosimilars - Insulin Aspart, Insulin Lispro, and Insulin Glargine in the U.S	21/09/23
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	28/08/23
Nanjing King-Friend Wins FDA Nod to Market Generic Version of Aloxi in US	17/08/23
NKFPharma Unit Gets US FDA's Nod for Plerixafor Injection	26/07/23
NKFPharma Unit Gets US FDA Nod for Cancer Drug	21/07/23
NKFPharma Unit Gets FDA Greenlight to Market Anesthetic in the US	27/06/23
NKFPharma Unit Gets FDA Nod for US Registration of Rocuronium Bromide	10/05/23
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	28/04/23
NKFPharma Gets Certification for Lung Cancer Drug	11/04/23
NKFPharma's Nadroparin Calcium Injection Passes Drug Regulator’s Evaluation	21/02/23
Nanjing King-friend Unit’s Anti-Cancer Drug Enters US Market	15/12/22
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	28/10/22
Chimigen Bio announced that it has received CNY 100 million in funding from Zhejiang Puhua Tianqin Equity Investment Management Co., Ltd., Lapam Capital, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd and other investors	22/09/22

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.

Acciones

603707

CNE100002WP3

Otros idiomas

Filtros